"In the field of health and medical investment, one must become increasingly agile and dynamically seize changes and opportunities because changes happen too quickly. In investment, only by staying focused can one continuously surpass oneself."
—Zhao Yucong, Vice President of Investment at 3E Bioventures
In recent years, the health and medical industry has witnessed a saying: changes happen faster than predictions. Synthetic biology, gene testing, digital healthcare, innovative drugs... The constant emergence of innovative technologies has brought revolutionary changes and business opportunities to the health and medical industry. Each wave of change is undoubtedly the best time to capture future trends.
As a seasoned investment expert, Zhao Yucong's past investment cases have mainly focused on synthetic biology, medical devices, clinical diagnostics, and consumer healthcare. He applies mature industry chain research methods to the study of companies in the health and medical field, accurately capturing high-quality investment projects. This has made him one of the leading figures in the "new generation" of China's health and medical industry investment.
From a newcomer to a manager, making a mark with solid research
Looking at Zhao Yucong's past experiences, he graduated with a degree in Mechanical Engineering from the University of Bath in the UK and obtained a Master's degree in Advanced Materials Science and Engineering from Imperial College London. He entered the investment industry at a time when artificial intelligence and biotechnology investments were flourishing.
In 2018, Zhao Yucong joined Shenzhen Bridgeone Capital Management Co., Ltd. as an Investment Manager, focusing on venture capital and deepening his expertise in artificial intelligence, medical devices, and clinical diagnostics. During his tenure, he conducted in-depth analysis of the in vitro diagnostic testing market, researched the serum-free culture medium and CDMO market in the field of large molecule innovative drugs, and successfully completed 11 investment projects. These included influential projects such as HeartID AI Defect Detection, Shenzhen Keyto, and C-Luminary Biotech , with a total investment of approximately 200 million yuan.
"To achieve such results, the key is to maintain curiosity and a learning mindset," he says. In his view, medical investment involves numerous fields, and technological updates are rapid, requiring continuous learning. Therefore, throughout his growth process, he consistently expanded his capabilities to various sub-industries within the broader healthcare sector.
Joining 3E Bioventures, closely following industry trends
In 2022, Zhao Yucong joined Beijing 3E Investment Management Co., Ltd. (3E Bioventures) as Vice President of Investment, focusing on cross-innovation in synthetic biology, regenerative materials, and digital therapy.
As a specialized fund company dedicated to the health and medical industry, 3E Bioventures has delved into various fields such as innovative drugs, medical devices, and clinical diagnostics for many years, with the team having accumulated investments in over 100 medical enterprises. Specializing in early-stage projects, 3E Bioventures has higher demands for industry analysis and investment decisions. In just over a year after taking office, Zhao Yucong completed investments in the development and production of recombinant botulinum toxin, efficiently advancing market analysis, distributor assessments, clinical interviews, and executive due diligence for botulinum toxin and growth hormone markets. Additionally, he deeply engaged in various projects such as biobased materials and home testing products, achieving substantial investment returns and leveraging investments to stimulate the development of the health and medical industry, gaining high recognition from the investment community, industry, and research institutions.
Zhao Yucong admits that investing in early-stage projects is much more challenging than investing in projects in the growth or late stages, requiring forward-looking judgments of industry trends. "You have to accurately grasp the changes and development trends of the industry and make corresponding arrangements. Instead of chasing trends, prepare for them before they arrive. Investment and industrial development complement each other. Making predictions in advance not only results in investment returns but, more importantly, provides powerful financial support at the most critical moment of industry development. That is the true value of investment."
Focusing on technological innovation to empower investments
With his professional investment capabilities and outstanding investment performance in the health and medical field, Zhao Yucong has gained high industry recognition. However, he hasn't rested on his laurels; instead, he continues to explore technological innovation. He utilizes cutting-edge technologies such as artificial intelligence, big data, and cloud computing to address key issues in health and medical investment, developing a series of intelligent investment technologies. The "Deep Learning-based Investment Research Intelligent Assistance System V1.0" is a typical representative.
This system is data-driven, with algorithmic logic at its core, using artificial intelligence technology to complete investment research information retrieval, data processing and analysis, research report writing, and risk alerts. It excels in interactive experience, dynamic data correlation, and deep learning capabilities compared to traditional investment research tools. It effectively solves problems such as large data volumes, abundant unstructured data, difficulty in information extraction, and poor data timeliness.
In practical applications, the system simplifies a significant amount of basic investment research information collection work, enhancing the comprehensiveness and efficiency of early-stage information gathering. In the analysis and research stage, the system provides a comprehensive analysis of economic cycles, economic phenomena, economic data, industry development trends, and the growth value of scientific and technological projects from a macro to micro perspective. Thanks to the system's assistance, in July 2021, Zhao Yucong and his team quickly completed research on the serum-free culture medium and CDMO industry in the field of large molecules, setting a new efficiency record for company research work and playing a crucial role in the company's successful co-investment in the project.
The world is full of uncertainty, and investment is a process of focusing through the clouds. Like setting sail on the sea, Zhao Yucong, as the "captain," is willing to use his professional investment system and technological means to anchor the target, accurately navigate, and, while ensuring stable returns for investors, help and accompany more early-stage medical innovation enterprises to grow and thrive. This, in turn, further propels the vigorous development of the entire health and medical industry.（Reporter: Fiona Chan）
Disclaimer:
This press release may contain forward-looking statements. Forward-looking statements describe future expectations, plans, results, or strategies (including product offerings, regulatory plans and business plans) and may change without notice. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements.
Source: Story.KISSPR.com
Release ID: 848909